Propel Bio Management, LLC
LOS ANGELES, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$188.6M2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.68.3%
What Changed This Quarter?
Top Holdings
PAGP
Plains GP
17.5%
ACHV
Achieve Life Sciences
16.6%
DCTH
Delcath Systems
5.1%
COLL
Collegium Pharmaceutical
4.7%
CORT
Corcept Therapeutics
4.6%
AQST
Aquestive Therapeutics
4.6%
MIST
Milestone Pharmaceuticals
4.3%
PHAT
Phathom Pharmaceuticals
4.3%
New / Increased
5 new · 5 increased
COLLNEW
Collegium Pharmaceutical
4.7%
CABANEW
Cabaletta Bio
2.1%
PROKNEW
Prokidney
1.8%
IRDNEW
Opus Genetics
0.7%
SGPNEW
Spyglass Pharma
0.6%
MAZE
Maze Therapeutics
2.8%
+338.4%
CRVS
Corvus Pharmaceuticals
1.6%
+275.5%
MIST
Milestone Pharmaceuticals
4.3%
+27.2%
Reduced / Exited
15 reduced · 4 sold out
AQST
Aquestive Therapeutics
4.6%
-80.7%
CORT
Corcept Therapeutics
4.6%
-44.9%
DCTH
Delcath Systems
5.1%
-30.6%
CLDX
Celldex Therapeutics
0.6%
-63.8%
ACHV
Achieve Life Sciences
16.6%
-4.2%
ZVRAEXIT
Zevra Therapeutics
1.9%
EYPTEXIT
Eyepoint
1.4%
SLNEXIT
Silence Therapeutics
1.1%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.